212 related articles for article (PubMed ID: 23800275)
41. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
42. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
43. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
[TBL] [Abstract][Full Text] [Related]
44. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
45. Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer.
Yang F; Gao B; Chen W; Du E; Liang Y; Hu X; Yang X
Medicine (Baltimore); 2018 Oct; 97(41):e12364. PubMed ID: 30313031
[TBL] [Abstract][Full Text] [Related]
46. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
47. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
Yang G; Rosen DG; Liu G; Yang F; Guo X; Xiao X; Xue F; Mercado-Uribe I; Huang J; Lin SH; Mills GB; Liu J
Clin Cancer Res; 2010 Aug; 16(15):3875-86. PubMed ID: 20505188
[TBL] [Abstract][Full Text] [Related]
48. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
49. Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.
Yang S; Li H; Liu Y; Ning X; Meng F; Xiao M; Wang D; Lou G; Zhang Y
Med Oncol; 2013 Mar; 30(1):324. PubMed ID: 23254963
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
51. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
52. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?
Kamura T; Yahata H; Amada S; Ogawa S; Sonoda T; Kobayashi H; Mitsumoto M; Kohno K; Kuwano M; Nakano H
Cancer; 1999 Jun; 85(11):2450-4. PubMed ID: 10357417
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of GRIM-19, NF-κB and IKK2 in patients with high-grade serous ovarian cancer.
Ilelis F; do Amaral NS; Alves MR; da Costa AABA; Calsavara VF; Lordello L; De Brot L; Soares FA; Rodrigues IS; Rocha RM
Pathol Res Pract; 2018 Feb; 214(2):187-194. PubMed ID: 29254797
[TBL] [Abstract][Full Text] [Related]
54. An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
Garand C; Guay D; Sereduk C; Chow D; Tsofack SP; Langlois M; Perreault E; Yin HH; Lebel M
Cancer Sci; 2011 Jul; 102(7):1410-7. PubMed ID: 21466612
[TBL] [Abstract][Full Text] [Related]
55. Overexpression of the X-linked ribosomal protein S4 predicts poor prognosis in patients with intrahepatic cholangiocarcinoma.
Kuang J; Li QY; Fan F; Shen NJ; Zhan YJ; Tang ZH; Yu WL
Oncol Lett; 2017 Jul; 14(1):41-46. PubMed ID: 28693133
[TBL] [Abstract][Full Text] [Related]
56. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
57. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
[TBL] [Abstract][Full Text] [Related]
58. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract][Full Text] [Related]
59. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
60. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
